The University of Chicago Header Logo

Connection

James Wallace to Bevacizumab

Back to Details
This is a "connection" page, showing publications James Wallace has written about Bevacizumab.
James Wallace
Connection Strength
0.025
Bevacizumab
  1. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Sep; 12(3):218-22.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.